肝硬化凝血功能紊乱与出血、血栓形成的研究进展

doi:10.3969/j.issn.1004-583X.2024.07.014

摘要/Abstract

摘要：

肝硬化患者凝血机制十分复杂,出血和血栓形成事件也时有发生,目前越来越多的研究证实了肝硬化体内“促凝-抗凝再平衡”的存在。该综述结合肝硬化凝血机制的最新研究进展,概述肝硬化患者凝血变化,并探讨其出血及血栓形成的发病机制及防治。

关键词: 肝硬化, 血液凝固, 血栓形成, 出血, 机制

中图分类号:

R575.2

朱萌然, 胡宵月, 苏芮, 杨旭旭, 漆平, 白云. 肝硬化凝血功能紊乱与出血、血栓形成的研究进展[J]. 临床荟萃, 2024, 39(7): 658-663.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.07.014

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I7/658

图/表 2

参考文献 55

[1]	Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis[J]. J Hepatol, 2017, 67(5): 950-956. doi: S0168-8278(17)32145-1 pmid: 28716745
[2]	Koupenova M, Kehrel BE, Corkrey HA, et al. Thrombosis and platelets: An update[J]. Eur Heart J, 2017, 38(11): 785-791. doi: 10.1093/eurheartj/ehw550 pmid: 28039338
[3]	张译之, 陈煜. 肝硬化患者的止血平衡改变[J]. 肝脏, 2020, 25(8): 786-788. doi: 10.1159/000339151 pmid: 22796658
[4]	Hugenholtz GCG, Lisman T, Stravitz RT. Thromboelastography does not predict outcome in different etiologies of cirrhosis[J]. Res Pract Thromb Haemost, 2017, 1(2): 275-285. doi: 10.1002/rth2.12037 pmid: 30046697
[5]	Fisher C, Patel VC, Stoy SH, et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure[J]. J Crit Care, 2018, 43: 54-60. doi: S0883-9441(17)30275-7 pmid: 28843665
[6]	丁靖诺, 赵卫峰. 肝硬化状态对血小板数目及功能变化的影响分析[J]. 胃肠病学和肝病学杂志, 2022, 31(7):725-730.
[7]	Naohisa W, Haruki U, Takashi S, et al. Impact of anti-GPIIb/IIIa antibody-producing B cells as a predictor of the response to lusutrombopag in thrombocytopenic patients with liver disease[J]. Digestive diseases, 2021, 39(3):234-242.
[8]	Lisman T, Arefaine B, Adelmeijer J, et al. Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease[J]. J Thromb Haemost, 2021, 19(1): 85-95.
[9]	Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis[J]. Gastroenterology, 2009, 137(6): 2105-2111. doi: 10.1053/j.gastro.2009.08.045 pmid: 19706293
[10]	Lisman T, Bos S, Intagliata NM. Mechanisms of enhanced thrombin-generating capacity in patients with cirrhosis[J]. J Thromb Haemost, 2018, 16(6): 1128-1131. doi: 10.1111/jth.14020 pmid: 29633495
[11]	El Bokl MA, Shawky A, Riad GS, et al. Procoagulant versus anticoagulant factors in cirrhotic patients[J]. Arab J Gastroenterol, 2014, 15(3-4): 123-129. doi: 10.1016/j.ajg.2014.08.003 pmid: 25249231
[12]	Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method[J]. Hepatology, 2010, 52(1): 249-255. doi: 10.1002/hep.23653 pmid: 20578143
[13]	Wilhelm AR, Parsons NA, Samelson-Jones BJ, et al. Activated protein C has a regulatory role in factor VIII function[J]. Blood, 2021, 137(18):2532-2543.
[14]	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis[J]. J Hepatol, 2022, 76(5): 1151-1184. doi: 10.1016/j.jhep.2021.09.003 pmid: 35300861
[15]	Francis JL, Armstrong DJ. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease[J]. Haemostasis, 1982, 11(4): 215-222. doi: 10.1159/000214666 pmid: 6290353
[16]	Hugenholtz GC, Macrae F, Adelmeijer J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen[J]. J Thromb Haemost, 2016, 14(5): 1054-1066. doi: 10.1111/jth.13278 pmid: 26833718
[17]	Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis[J]. Hepatology, 2003, 38(1): 230-237. pmid: 12830006
[18]	Rijken DC, Kock EL, Guimarães AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests[J]. J Thromb Haemost, 2012, 10(10): 2116-2122. doi: 10.1111/j.1538-7836.2012.04901.x pmid: 22906184
[19]	Leebeek FW, Kluft C, Knot EA, et al. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis[J]. Gastroenterology, 1991, 101(5): 1382-1390. doi: 10.1016/0016-5085(91)90092-y pmid: 1718809
[20]	Hersch SL, Kunelis T, Francis RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibitor[J]. Blood, 1987, 69(5): 1315-1319. pmid: 2436684
[21]	Labidi A, Baccouche H, Fekih M, et al. The relationship between coagulation disorders and the risk of bleeding in cirrhotic patients[J]. Ann Hepatol, 2019, 18(4): 627-632. doi: S1665-2681(19)30071-7 pmid: 31097395
[22]	Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 73(1): 366-413. doi: 10.1002/hep.31646 pmid: 33219529
[23]	黄志寅, 高锦航. 保护门静脉——从病理生理到临床处理决策[J]. 临床肝胆病杂志, 2021, 37(12): 2760-2763.
[24]	Muciño-Bermejo J, Carrillo-Esper R, Uribe M, et al. Coagulation abnormalities in the cirrhotic patient[J]. Ann hepatol, 2013, 12(5): 713-724. pmid: 24018489
[25]	Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease[J]. Clin Gastroenterol H, 2010, 8(10): 899-902; quiz e109. doi: 10.1016/j.cgh.2010.06.018 pmid: 20601131
[26]	唐承薇. 慢性肝病与血小板减少:临床处理观念的转变[J]. 实用肝脏病杂志, 2019, 22(4): 457-458.
[27]	Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy[J]. Brit J Anaesth, 2010, 105(2): 116-121.
[28]	Giannini EG, Giambruno E, Brunacci M, et al. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients[J]. Ann Hepatol, 2018, 17(5): 830-835. doi: 10.5604/01.3001.0012.0775 pmid: 30145561
[29]	Drolz A, Horvatits T, Roedl K, et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis[J]. Hepatology, 2016, 64(2): 556-568. doi: 10.1002/hep.28628 pmid: 27124745
[30]	Budnick IM, Davis JPE, Sundararaghavan A, et al. Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically Ill cirrhosis patients[J]. Thromb Haemostasis, 2021, 121(10): 1317-1325. doi: 10.1055/a-1355-3716 pmid: 33450778
[31]	Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis[J]. J Hepatol, 2022, 76(6): 1291-1305. doi: 10.1016/j.jhep.2021.11.004 pmid: 35589251
[32]	祁兴顺, 杨玲. 肝硬化门静脉血栓管理专家共识(2020年,上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674.
[33]	Jepsen P, Tapper EB, Deleuran T, et al. Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: A danish nation-wide cohort study[J]. Hepatology, 2021, 74(5): 2725-2734. doi: 10.1002/hep.32019 pmid: 34137045
[34]	Violi F, Ferro D. Clotting activation and hyperfibrinolysis in cirrhosis: Implication for bleeding and thrombosis[J]. Semin Thromb Hemost, 2013, 39(4): 426-433. doi: 10.1055/s-0033-1334144 pmid: 23487343
[35]	Semeraro N, Biondi A, Lorenzet R, et al. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites[J]. Immunology, 1983, 50(4): 529-535. pmid: 6654386
[36]	Moore KL, Andreoli SP, Esmon NL, et al. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro[J]. J Clin Invest, 1987, 79(1): 124-130. doi: 10.1172/JCI112772 pmid: 3025256
[37]	Lin HC, Yang YY, Tsai TH, et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension[J]. J Hepatol, 2011, 54(6): 1145-1153.
[38]	Schierwagen R, Alvarez-Silva C, Madsen MSA, et al. Circulating microbiome in blood of different circulatory compartments[J]. Gut, 2019, 68(3): 578-580. doi: 10.1136/gutjnl-2018-316227 pmid: 29581241
[39]	Violi F, Ferro D, Basili S, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients[J]. Thromb haemostasis, 1997, 77(1): 44-47. pmid: 9031447
[40]	Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors[J]. J Hepatol, 2021, 75(6): 1367-1376. doi: 10.1016/j.jhep.2021.07.020 pmid: 34333101
[41]	He Y, Yuan S, Guo X, et al. Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis[J]. BMC Gastroenterol, 2021, 21(1): 253. doi: 10.1186/s12876-021-01832-3 pmid: 34098892
[42]	Driever EG, Von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus[J]. Hepatology, 2022, 75(4): 898-911.
[43]	Anwar MA, Shalhoub J, Lim CS, et al. The effect of pressure-induced mechanical stretch on vascular wall differential gene expression[J]. J Vasc Res, 2012, 49(6): 463-478.
[44]	Ahanchi SS, Tsihlis ND, Kibbe MR. The role of nitric oxide in the pathophysiology of intimal hyperplasia[J]. J Vasc Surg, 2007, 45 (Suppl A): A64-73.
[45]	Sigel B, Swami V, Can A, et al. Intimal hyperplasia producing thrombus organization in an experimental venous thrombosis model[J]. J Vasc Surg, 1994, 19(2): 350-360. pmid: 8114194
[46]	肖春桃, 李贤秋, 甘佩灵, 等. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响[J]. 临床肝胆病杂志, 2021, 37(8):1829-1835.
[47]	何青莲, 余保平, 肖勇. 肝硬化食管胃静脉曲张出血患者内镜治疗后再出血的危险因素分析[J]. 肝脏, 2023, 28(1):55-60.
[48]	Wang L, Guo X, Bai Z, et al. Impact of asymptomatic superior mesenteric vein thrombosis on the outcomes of patients with liver cirrhosis[J]. Thromb Haemostasis, 2022, 122(12): 2019-2029.
[49]	Rugivarodom M, Charatcharoenwitthaya P. Nontumoral portal vein thrombosis: A challenging consequence of liver cirrhosis[J]. J Clin Transl Hepato, 2020, 8(4): 432-444.
[50]	Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: Results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667.
[51]	Noronha Ferreira C, Marinho RT, Cortez-Pinto H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study[J]. Liver int, 2019, 39(8): 1459-1467. doi: 10.1111/liv.14121 pmid: 31021512
[52]	De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis[J]. Liver int, 2017, 37(5): 694-699. doi: 10.1111/liv.13285 pmid: 27778440
[53]	Hum J, Shatzel JJ, Jou JH, et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis[J]. Eur J Haematol, 2017, 98(4): 393-397. doi: 10.1111/ejh.12844 pmid: 28009449
[54]	Mort JF, Davis JPE, Mahoro G, et al. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis[J]. Clin Gastroenterol H, 2021, 19(7): 1436-1442. doi: 10.1016/j.cgh.2020.08.007 pmid: 32777555
[55]	Semmler G, Pomej K, Bauer DJM, et al. Safety of direct oral anticoagulants in patients with advanced liver disease[J]. Liver int, 2021, 41(9): 2159-2170. doi: 10.1111/liv.14992 pmid: 34152697

肝硬化凝血功能紊乱与出血、血栓形成的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 55

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于菁怡, 司元国, 兰翠霞, 邢家璇. 新冠肺炎患者院外使用利伐沙班抗凝安全性和有效性的meta分析[J]. 临床荟萃, 2024, 39(6): 485-493.
[2]	王娇燕, 严超, 应可净. 气道慢性炎症性疾病并发静脉血栓栓塞症的研究进展[J]. 临床荟萃, 2024, 39(5): 470-474.
[3]	匡竞, 滕双芩, 申彤彤, 闫怡然, 申川, 王玮, 王亚东, 赵彩彦. 门脉性肺动脉高压研究进展[J]. 临床荟萃, 2024, 39(4): 352-356.
[4]	陈岚, 李叶琼, 冶秀鹏. 费城染色体阴性骨髓增殖性肿瘤患者血栓形成影响因素[J]. 临床荟萃, 2024, 39(4): 370-375.
[5]	孙庆, 王海龙, 米庆, 乐暾, 牟华明. 外泌体在心力衰竭发生发展中的作用及临床价值[J]. 临床荟萃, 2024, 39(3): 259-263.
[6]	金鑫, 吴金玲, 尹丽丽. 持续性植物状态促醒机制及治疗研究进展[J]. 临床荟萃, 2024, 39(2): 172-176.
[7]	王琦, 陈宏. 维生素D在支气管哮喘和慢性阻塞性肺疾病治疗中的应用进展[J]. 临床荟萃, 2024, 39(1): 88-91.
[8]	马丽娜, 焦焕利, 曹振华. 慢性非缺血性心功能衰竭合并血栓栓塞及药物治疗研究进展[J]. 临床荟萃, 2024, 39(1): 75-79.
[9]	刘岩, 刘琼, 梁晓梅, 刘冰. 以发热为主要症状的自发性肾出血继发感染1例并文献复习[J]. 临床荟萃, 2023, 38(9): 823-826.
[10]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[11]	左腾, 王俊祥. 血清阴性类风湿关节炎发病机制的研究进展[J]. 临床荟萃, 2023, 38(8): 753-756.
[12]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[13]	高福生, 张川, 展玉涛. 经内镜逆行性胰胆管造影术后并发症相关影响因素分析及防治进展[J]. 临床荟萃, 2023, 38(6): 550-553.
[14]	贾丽娜, 吴美妮, 尹昌浩. 2型糖尿病认知功能障碍发病机制的研究进展[J]. 临床荟萃, 2023, 38(6): 554-558.
[15]	辛在娥. 误诊为脑膜炎的蛛网膜下腔出血1例及文献复习[J]. 临床荟萃, 2023, 38(5): 448-450.